Trial Profile
Risk-Stratified Randomized Phase III Testing of Blinatumomab (NSC#765986) in First Relapse of Childhood B-Lymphoblastic Leukemia (B-ALL)
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 23 Nov 2023
Price :
$35
*
At a glance
- Drugs Blinatumomab (Primary) ; Asparaginase; Asparaginase; Cyclophosphamide; Cytarabine; Cytarabine; Cytarabine; Dexamethasone; Dexamethasone; Etoposide; Folinic acid; Folinic acid; Hydrocortisone; Mercaptopurine; Methotrexate; Methotrexate; Methotrexate; Mitoxantrone; Pegaspargase; Tioguanine; Vincristine
- Indications Precursor B-cell lymphoblastic leukaemia-lymphoma; Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Registrational; Therapeutic Use
- 26 Sep 2023 Planned End Date changed from 30 Apr 2024 to 22 Sep 2024.
- 31 May 2023 Primary endpoint (DFS of low risk (LR) relapse patients) has been met according result published in the Journal of Clinical Oncology
- 31 May 2023 Results assessing to compare survival of patients with low-risk (LR) first relapse of B-ALL treated with chemotherapy alone or chemotherapy plus blinatumomab. published in the Journal of Clinical Oncology